[AI Generated AI in Drug Discovery News]

• Turbine is utilizing a recently secured $25 million in Series B funding to advance its "lab-in-the-loop" AI platform that simulates biological processes to reduce the cost and risk of drug discovery.

• Evinova has established strategic partnerships with AstraZeneca, Astellas, and Bristol Myers Squibb to integrate AI across the drug development spectrum, focusing on clinical trial data analysis and early-stage candidate selection.

• Owkin has launched K Pro, an AI co-pilot that uses federated learning and biological reasoning to analyze fragmented biomedical data, aiming to significantly accelerate drug discovery timelines and enhance precision medicine.